Literature DB >> 10415152

Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations.

C J Ladner1, J M Lee.   

Abstract

M(1) muscarinic acetylcholine receptor (M(1)AchR)-G protein coupling, as measured by high-affinity agonist binding, was examined in membranes prepared from postmortem human temporal cortex (Brodmann area 38) from individuals with Alzheimer's disease (AD, n = 8) and age-matched controls (n = 6). Binding competitions between the M(1)AchR-selective antagonist [(3)H]pirenzepine ([(3)H]PZ) and muscarinic agonists carbachol, acetylcholine, oxotremorine, and oxotremorine M were conducted. In the presence of 1 mM MgCl(2), the inhibition of [(3)H]PZ binding by carbachol, acetylcholine, or oxotremorine M was best described by a two-affinity state model for control and AD cases, while oxotremorine binding affinity was best fit to a single-state model. Although both control and AD groups had similar K(D) values for the high- and low-affinity agonist binding sites, the proportion of M(1)AchRs exhibiting high affinity for carbachol and acetylcholine was reduced by 48 and 33%, respectively, in AD membranes relative to controls (P < 0.05). No changes in the binding of the oxotremorine M or oxotremorine were noted. The nonhydrolyzable guanine nucleotide GppNHp (100 microM) reduced the proportion of M(1)AchRs with high affinity for agonists in both control and AD membranes. Substitution of 1 mM MnCl(2) for MgCl(2) restored high-affinity carbachol binding at the M(1)AchR in AD membranes similar to that seen in controls. In the presence of 1 mM MnCl(2), agonist binding in controls did not differ from 1 mM MgCl(2). In the absence of cations (1 mM EDTA), no differences between control and AD M(1)AchR carbachol binding were observed. Thus, the loss of high-affinity agonist binding at the M(1)AchR in AD is dependent on the agonist and cation studied. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415152     DOI: 10.1006/exnr.1999.7116

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  5 in total

1.  Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease.

Authors:  Cassia R Overk; Christian C Felder; Yuan Tu; Doug A Schober; Kelly R Bales; Joanne Wuu; Elliott J Mufson
Journal:  J Chem Neuroanat       Date:  2010-03-27       Impact factor: 3.052

2.  Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.

Authors:  Elizabeth Scarr; Catriona McLean; Brian Dean
Journal:  J Neural Transm (Vienna)       Date:  2016-09-29       Impact factor: 3.575

Review 3.  M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Shangtong Jiang; Yanfang Li; Cuilin Zhang; Yingjun Zhao; Guojun Bu; Huaxi Xu; Yun-Wu Zhang
Journal:  Neurosci Bull       Date:  2014-03-03       Impact factor: 5.203

4.  A network pharmacology-based study on Alzheimer disease prevention and treatment of Qiong Yu Gao.

Authors:  Jie-Shu You; Chen-Yue Li; Wei Chen; Xia-Lin Wu; Li-Jie Huang; Ren-Kai Li; Fei Gao; Ming-Yue Zhang; Huan-Lan Liu; Wei-Ling Qu
Journal:  BioData Min       Date:  2020-04-25       Impact factor: 2.522

Review 5.  Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging.

Authors:  Vladimir Shalgunov; Aren van Waarde; Jan Booij; Martin C Michel; Rudi A J O Dierckx; Philip H Elsinga
Journal:  Med Res Rev       Date:  2018-11-18       Impact factor: 12.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.